Literature DB >> 16844267

Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial.

Michael de Vrese1, Petra Winkler, Peter Rautenberg, Timm Harder, Christian Noah, Christiane Laue, Stephan Ott, Jochen Hampe, Stefan Schreiber, Knut Heller, Jürgen Schrezenmeir.   

Abstract

To investigate the effect of long-term consumption of probiotic bacteria on viral respiratory tract infections (common cold, influenza), a randomized, double blind, controlled intervention study was performed during two winter/spring periods (3 and 5 month). Four hundred and seventy-nine healthy adults were supplemented daily with vitamins plus minerals with or without probiotic lactobacilli and bifidobacteria. The intake of the probiotic had no effect on the incidence of common cold infections (verum=158, control=153 episodes, influenza was not observed), but significantly shortened duration of episodes by almost 2 days (7.0+/-0.5 versus 8.9+/-1.0 days, p=0.045), reduced the severity of symptoms and led to larger increases in cytotoxic T plus T suppressor cell counts and in T helper cell counts.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16844267     DOI: 10.1016/j.vaccine.2006.05.048

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  52 in total

1.  The role of nutrition in enhancing immunity in aging.

Authors:  Munkyong Pae; Simin Nikbin Meydani; Dayong Wu
Journal:  Aging Dis       Date:  2011-09-30       Impact factor: 6.745

2.  Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections.

Authors:  Anna Berggren; Irini Lazou Ahrén; Niklas Larsson; Gunilla Önning
Journal:  Eur J Nutr       Date:  2010-08-28       Impact factor: 5.614

Review 3.  Health benefits of probiotics: are mixtures more effective than single strains?

Authors:  C M C Chapman; G R Gibson; I Rowland
Journal:  Eur J Nutr       Date:  2011-01-13       Impact factor: 5.614

4.  Nutritional and Physical Activity Interventions to Improve Immunity.

Authors:  Glen Davison; Corinna Kehaya; Arwel Wyn Jones
Journal:  Am J Lifestyle Med       Date:  2014-11-25

Review 5.  Are vaccination models suitable to determine whether probiotics have beneficial health effects in the general population?

Authors:  Nicholas P West; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

Review 6.  Antiviral potential of lactic acid bacteria and their bacteriocins.

Authors:  I Al Kassaa; D Hober; M Hamze; N E Chihib; D Drider
Journal:  Probiotics Antimicrob Proteins       Date:  2014-12       Impact factor: 4.609

7.  Role of short-term use of L. acidophilus DDS-1 and B. lactis UABLA-12 in acute respiratory infections in children: a randomized controlled trial.

Authors:  S V Gerasimov; V A Ivantsiv; L M Bobryk; O O Tsitsura; L P Dedyshin; N V Guta; B V Yandyo
Journal:  Eur J Clin Nutr       Date:  2015-10-14       Impact factor: 4.016

8.  Commensal bacteria calibrate the activation threshold of innate antiviral immunity.

Authors:  Michael C Abt; Lisa C Osborne; Laurel A Monticelli; Travis A Doering; Theresa Alenghat; Gregory F Sonnenberg; Michael A Paley; Marcelo Antenus; Katie L Williams; Jan Erikson; E John Wherry; David Artis
Journal:  Immunity       Date:  2012-06-14       Impact factor: 31.745

9.  Impact of Probiotics for Reducing Infections in Veterans (IMPROVE): Study protocol for a double-blind, randomized controlled trial to reduce carriage of Staphylococcus aureus.

Authors:  Shoshannah Eggers; Anna Barker; Susan Valentine; Timothy Hess; Megan Duster; Nasia Safdar
Journal:  Contemp Clin Trials       Date:  2016-11-09       Impact factor: 2.226

10.  Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions.

Authors:  Jennifer Daniel-Johnson; Susan Leitman; Harvey Klein; Harvey Alter; Agnes Lee-Stroka; Phillip Scheinberg; Jeremy Pantin; Karen Quillen
Journal:  Transfusion       Date:  2009-05-11       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.